← Back to feedRead original →
VERIFIEDET Finance·positive
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid
AI Summary
- ·Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries.
- ·The ratings follow Sun Pharma's proposed acquisition of US-based Organon & Co.
- ·The acquisition is expected to significantly bolster Sun Pharma's business position and revenue base.